Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Salmeterol Inhalation Powder Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01089127
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
69
States / cities
Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

NCT02573233
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

NCT01772147
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 1 Interventional

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

NCT02437604
View directory record Official record
Conditions
Asthma
Interventions
Treatment A: Fp MDPI, Treatment B: FS MDPI, Treatment C Flovent, Treatment D: Advair
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Raleigh, North Carolina • Edmond, Oklahoma • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02139644
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
76
States / cities
Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Sep 9, 2026, 1:56 AM EDT
Not listed Phase 4 Interventional

Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography

NCT01361984
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD, Emphysema, Chronic Bronchitis
Interventions
Nebulized arformoterol, Salmeterol
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

NCT01772134
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

NCT02924688
View directory record Official record
Conditions
Asthma
Interventions
FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI)
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

NCT02980133
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate, Fluticasone Propionate/Salmeterol, Placebo MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

NCT01147848
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone propionate/salmeterol Inhalation Powder, Placebo (1), Placebo (2)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Huntington Beach, California • Los Angeles, California • Riverside, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

NCT00529529
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
56
States / cities
Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2011 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

NCT00821093
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 µg, Salmeterol 50 µg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
74
States / cities
Anniston, Alabama • Fairhope, Alabama • Jasper, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

NCT02301975
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler, Placebo inhalation powders via ELLIPTA inhaler, Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler, Placebo inhalation powder via ACCUHALER/DISKUS inhaler, Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
1,526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
34
States / cities
Huntington Beach, California • Riverside, California • Rolling Hills Estates, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

NCT02215122
View directory record Official record
Conditions
Asthma, COPD
Interventions
MGR001, Advair® Diskus®, Seretide™ Accuhaler™
Drug
Lead sponsor
Mylan Pharma UK Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)

NCT00565266
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, salmeterol xinafoate, beclomethasone dipropionate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

NCT02175771
View directory record Official record
Conditions
Persistent Asthma
Interventions
Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

NCT03394989
View directory record Official record
Conditions
Bronchial Asthma
Interventions
Fluticasone propionate/salmeterol 100/50 µg, Placebo, Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT
Drug · Other
Lead sponsor
Cipla Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 9, 2026, 1:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

NCT00568347
View directory record Official record
Conditions
COPD
Interventions
fluticasone 100mcg/ salmeterol 50mcg, fluticasone 250/salmeterol 50, Salmeterol, salmeterol and fluticasone propionate
Drug
Lead sponsor
Arthur F Gelb MD
Individual
Eligibility
20 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

NCT01772368
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, FS MDPI, Advair Diskus, Albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
10
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02141854
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, Albuterol/salmeterol HFA MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
85
States / cities
Birmingham, Alabama • Little Rock, Alaska • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 2 Interventional

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

NCT00403286
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Fluticasone Propionate/Formoterol Fumarate, Fluticasone Propionate, Formoterol Fumarate, Fluticasone Propionate/Salmeterol Xinafoate, Placebo
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
49
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2009 · Synced Sep 9, 2026, 1:56 AM EDT
Terminated Phase 3 Interventional Results available

Tiotropium/Salmeterol Inhalation Powder in COPD

NCT00668772
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium/Salmeterol, Salmeterol, Placebo, Tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
16
States / cities
Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01706328
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
16
States / cities
Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01817764
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 9, 2026, 1:56 AM EDT